Abstract
We report the results of an aggressive salvage regimen in 2 patients with advanced-stage leukemic-phase mantle cell lymphoma who were refractory to previous conventional therapies.We combined multiple phases of a cytoreductive regimen including rituximab and sequential high-dose treatment with autologous stem cell transplantation (ASCT).The regimen consisted of a debulking phase with fludarabine, idarubicin, high-dose cytarabine, and high-dose methotrexate; a mobilization and in vivo purging phase with rituximab, cyclophosphamide, and granulocyte colony-stimulating factor; high-dose sequential chemotherapy with etoposide, mitoxantrone, and melphalan followed by ASCT; and, finally, posttransplantation consolidation with rituximab for treatment of minimal residual disease.With this regimen, these 2 refractory patients with multiple poor prognostic factors are in complete remission at 41 and 42 months following transplantation. Although the fact that these 2 patients are still in remission beyond 3 years after ASCT is encouraging, we need a longer follow-up to comment on their long-term survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armitage JO, Weisenburger DD. New approaches to classifying non-Hodgkin’s lymphoma: clinical features of the major subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–2795.
Weisenburger DD, Armitage JO. Mantle cell lymphoma: an entity comes of age. Blood. 1996;87:4483–4494.
Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective compared analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16:1922–1930.
Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol. 2002;29(suppl 2):56–69.
Vose JM, Bierman PF, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2000;6:640–645.
Rummel MJ, Chow KU, Jager E, et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol. 1999;10:115–117.
Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16:13–18.
Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803–3809.
Vanderberghe E, Ruiz de Elvira C, Isaacson P, et al. Does transplantation improve outcome in mantle cell lymphoma? A study from the EBMT [abstract]. Blood. 2000;96:482a.
Freedman AS, Gribben JG, Nadler LM. High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin’s lymphoma. Leuk Lymphoma. 1998;28:219–230.
Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864–869.
Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol. 2002;116:229–235.
Molina A, Nademanee A, O’Donnel MR, et al. Autologous and allogeneic stem cell transplantation for poor-risk mantle cell lymphoma: the City of Hope experience [abstract]. Blood. 1998;92:459a.
Brugger W, Hirsch J, Repp R, et al. Treatment of follicular and mantle cell non-Hodgkin’s lymphoma with anti-CD20 antibody rituximab after high-dose chemotherapy with autologous CD34+ enriched peripheral blood stem cell transplantation [abstract]. Blood. 2000;96:482a.
Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin’s lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89:724–731.
Zinzani PL, Magagnoli M, Moretti L, et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica. 1999;84:1002–1006.
Zinzani PL, Bebdandi M, Gherlinzoni F, Merla E, Gozzetti A, Tura S. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin’s lymphoma. Haematologica. 1996;81:168–171.
Dreger P, Martin S, Kuse R, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J. 2000;1:87–94.
Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–2078.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Oyan, B., Koc, Y. & Kansu, E. Successful Salvage with High-Dose Sequential Chemotherapy Coupled with In Vivo Purging and Autologous Stem Cell Transplantation in 2 Patients with Primary Refractory Mantle Cell Lymphoma Presenting in the Leukemic Phase. Int J Hematol 81, 155–158 (2005). https://doi.org/10.1532/IJH97.E0303
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.E0303